BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 7, 2014, Pages 1596-1604

  Del Campo, Marta ^a,b   Hoozemans, Jeroen J M ^a   Dekkers, Lois Lee ^a   Rozemuller, Annemieke J ^a   Korth, Carsten ^c   Müller Schiffmann, Andreas ^c   Scheltens, Philip ^b   Blankenstein, Marinus A ^a   Jimenez, Connie R ^a   Veerhuis, Robert ^a   Teunissen, Charlotte E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Alzheimer's disease; Amyloid plaques; BRI2; Human hippocampus; Pathogenesis

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FURIN; MEMBRANE PROTEIN; PROTEIN BRI2; PROTEIN SPPL2B; PROTEINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENTATE HILUS; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; SUBICULUM;

ALZHEIMER'S DISEASE; AMYLOID PLAQUES; BRI2; HUMAN HIPPOCAMPUS; PATHOGENESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MULTIPROTEIN COMPLEXES; PLAQUE, AMYLOID; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84903368137     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.01.007     Document Type: Article

References (46)

1. Akiyama H., Kondo H., Arai T., Ikeda K., Kato M., Iseki E., Schwab C., McGeer P.L. Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol. 2004, 107:53-58.
2. Bekris L.M., Lutz F., Li G., Galasko D.R., Farlow M.R., Quinn J.F., Kaye J.A., Leverenz J.B., Tsuang D.W., Montine T.J., Peskind E.R., Yu C.-E. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiol. Aging 2012, 33:2229.e1-2229.e9.
3. Bernstein H.-G., Bukowska A., Krell D., Bogerts B., Ansorge S., Lendeckel U. Comparative localization of ADAMs 10 and 15 in human cerebral cortex normal aging, Alzheimer disease and Down syndrome. J.Neurocytol. 2003, 32:153-160.
4. Bernstein H.-G., Stricker R., Lendeckel U., Bertram I., Dobrowolny H., Steiner J., Bogerts B., Reiser G. Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains. Age (Dordr) 2009, 31:11-25.
5. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Colciaghi F., Marcello E., Borroni B., Zimmermann M., Caltagirone C., Cattabeni F., Padovani A., Di Luca M. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 2004, 62:498-501.
8. Endres K., Fahrenholz F. Regulation of alpha-secretase ADAM10 expression and activity. Exp. Brain Res. 2012, 217:343-352.
9. Fotinopoulou A., Tsachaki M., Vlavaki M., Poulopoulos A., Rostagno A., Frangione B., Ghiso J., Efthimiopoulos S. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J.Biol. Chem. 2005, 280:30768-30772.
10. Friedmann E., Hauben E., Maylandt K., Schleeger S., Vreugde S., Lichtenthaler S.F., Kuhn P.-H., Stauffer D., Rovelli G., Martoglio B. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat. Cell Biol. 2006, 8:843-848.
11. Garringer H.J., Murrell J., D'Adamio L., Ghetti B., Vidal R. Modeling familial British and Danish dementia. Brain Struct. Funct. 2010, 214:235-244.
12. Garringer H.J., Murrell J., Sammeta N., Gnezda A., Ghetti B., Vidal R. Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice. PLoS One 2013, 8:e56426.
13. Kilger E., Buehler A., Woelfing H., Kumar S., Kaeser S.A., Nagarathinam A., Walter J., Jucker M., Coomaraswamy J. BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J.Biol. Chem. 2011, 286:37446-37457.
14. Kim J., Miller V.M., Levites Y., West K.J., Zwizinski C.W., Moore B.D., Troendle F.J., Bann M., Verbeeck C., Price R.W., Smithson L., Sonoda L., Wagg K., Rangachari V., Zou F., Younkin S.G., Graff-Radford N., Dickson D., Rosenberry T., Golde T.E. BRI2 (ITM2b) inhibits Abeta deposition invivo. J.Neurosci. 2008, 28:6030-6036.
15. Kim S.H., Wang R., Gordon D.J., Bass J., Steiner D.F., Lynn D.G., Thinakaran G., Meredith S.C., Sisodia S.S. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat. Neurosci. 1999, 2:984-988.
16. Kim S.H., Wang R., Gordon D.J., Bass J., Steiner D.F., Thinakaran G., Lynn D.G., Meredith S.C., Sisodia S.S. Familial British dementia: expression and metabolism of BRI. Ann. N. Y. Acad. Sci. 2000, 920:93-99.
17. Korth C., Stierli B., Streit P., Moser M., Schaller O., Fischer R., Schulz-Schaeffer W., Kretzschmar H., Raeber A., Braun U., Ehrensperger F., Hornemann S., Glockshuber R., Riek R., Billeter M., Wüthrich K., Oesch B. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997, 390:74-77.
18. Kuhn P.-H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
19. Lashley T., Revesz T., Plant G., Bandopadhyay R., Lees A., Frangione B., Wood N., de Silva R., Ghiso J., Rostagno A., Holton J. Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. Ne. Neuropathol. Appl. Neurobiol. 2008, 34:492-505.
20. Marcinkiewicz M., Seidah N.G. Coordinated expression of beta-amyloid precursor protein and the putative ß-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J.Neurochem. 2000, 75:2133-2143.
21. Martin L., Fluhrer R., Haass C. Substrate requirements for SPPL2b-dependent regulated intramembrane proteolysis. J.Biol. Chem. 2009, 284:5662-5670.
22. Martin L., Fluhrer R., Reiss K., Kremmer E., Saftig P., Haass C. Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b. J.Biol. Chem. 2008, 283:1644-1652.
23. Matsuda S., Giliberto L., Matsuda Y., Davies P., McGowan E., Pickford F., Ghiso J., Frangione B., D'Adamio L. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J.Biol. Chem. 2005, 280:28912-28916.
24. Matsuda S., Giliberto L., Matsuda Y., McGowan E.M., D'Adamio L. BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J.Neurosci. 2008, 28:8668-8676.
25. Matsuda S., Matsuda Y., Snapp E.L., D'Adamio L. Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiol. Aging 2009, 32:1400-1408.
26. Matsuda S., Tamayev R., D'Adamio L. Increased AβPP processing in familial Danish dementia patients. J.Alzheimers Dis. 2011, 27:385-391.
27. Nelson P.T., Jicha G.A., Schmitt F.A., Liu H., Davis D.G., Mendiondo M.S., Abner E.L., Markesbery W.R. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J.Neuropathol. Exp. Neurol. 2007, 66:1136-1146.
28. Peng S., Fitzen M., Jörnvall H., Johansson J. The extracellular domain of Bri2 (ITM2B) binds the ABri peptide (1-23) and amyloid beta-peptide (Abeta1-40): implications for Bri2 effects on processing of amyloid precursor protein and Abeta aggregation. Biochem. Biophys. Res. Commun. 2010, 393:356-361.
29. Reisberg B., Ferris S., De Leon M.J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 1982, 139:1136-1139.
30. Rostagno A., Tomidokoro Y., Lashley T., Ng D., Plant G., Holton J., Frangione B., Revesz T., Ghiso J. Chromosome 13 dementias. Cell Mol. Life Sci. 2005, 62:1814-1825.
31. Tamayev R., D'Adamio L. Memory deficits of British dementia knock-in mice are prevented by Aβ precursor protein haploinsufficiency. J.Neurosci. 2012, 32:5481-5485.
32. Tamayev R., Giliberto L., Li W., D'Abramo C., Arancio O., Vidal R., D'Adamio L. Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis. J.Neurosci. 2010, 30:14915-14924.
33. Tamayev R., Matsuda S., Arancio O., D'Adamio L. β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol. Med. 2012, 4:171-179.
34. Tamayev R., Matsuda S., Fà M., Arancio O., Adamio L.D. Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. PNAS 2010, 107:20822-20827.
35. Tamayev R., Matsuda S., Giliberto L., Arancio O., D'Adamio L. APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant. EMBO J. 2011, 30:2501-2509.
36. Thal D.R., Capetillo-Zarate E., Del Tredici K., Braak H. The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006, 6:1-9.
37. Tsachaki M., Fotinopoulou A., Slavi N., Zarkou V., Ghiso J., Efthimiopoulos S. BRI2 interacts with BACE1 and regulates its cellular levels by promoting its degradation and reducing its mRNA levels. Curr. Alzheimer Res. 2013, 10:532-541.
38. Tsachaki M., Ghiso J., Efthimiopoulos S. BRI2 as a central protein involved in neurodegeneration. Biotechnol. J. 2008, 3:1548-1554.
39. Tsachaki M., Ghiso J., Rostagno A., Efthimiopoulos S. BRI2 homodimerizes with the involvement of intermolecular disulfide bonds. Neurobiol. Aging 2010, 31:88-98.
40. Tsachaki M., Serlidaki D., Fetani A., Zarkou V., Rozani I., Ghiso J., Efthimiopoulos S. Glycosylation of BRI2 on asparagine 170 is involved in its trafficking to the cell surface but not in its processing by furin or ADAM10. Glycobiology 2011, 21:1382-1388.
41. Verwey N.A., Hoozemans J.J.M., Korth C., van Royen M.R., Prikulis I., Wouters D., Twaalfhoven H.A.M., van Haastert E.S., Schenk D., Scheltens P., Rozemuller A.J.M., Blankenstein M.A., Veerhuis R. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide. Amyloid 2013, 20:179-187.
42. Vidal R., Frangione B., Rostagno A., Mead S., Révész T., Plant G., Ghiso J. Astop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999, 399:776-781.
43. Vidal R., Revesz T., Rostagno A., Kim E., Holton J.L., Bek T., Bojsen-Møller M., Braendgaard H., Plant G., Ghiso J., Frangione B. Adecamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc. Natl. Acad. Sci. U.S.A 2000, 97:4920-4925.
44. Willander H., Hermansson E., Johansson J., Presto J. BRICHOS domain associated with lung fibrosis, dementia and cancer-a chaperone that prevents amyloid fibril formation?. FEBS J. 2011, 278:3893-3904.
45. Willander H., Presto J., Askarieh G., Biverstål H., Frohm B., Knight S.D., Johansson J., Linse S. BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. J.Biol. Chem. 2012, 287:31608-31617.
46. Yamaguchi H., Haga C., Hirai S., Nakazato Y., Kosaka K. Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol. 1990, 79:569-572.